The conference circuit is an all-important part of the growth process for small and start-up companies. Dataram Corp. (NASDAQ: DRAM) announced in a press release that it would be presenting at the Source Capital Group’s 2016 Disruptive Growth and Healthcare Conference in February 2016. This conference will feature executives from life science companies focusing on solutions to unmet medical needs and growth companies with disruptive technologies and business models.

Presenting at conferences to get your name out there and meeting potential institutional investors is a vital part of getting access to the capital needed to grow and expand your business. This conference, in particular, is expected to have in attendance more than 400 institutional and accredited investors, family offices, analysts, registered investment advisors, and wealth managers, as well as Source Capital representatives and their clients.

Source Capital is a seasoned investment-banking group with a myriad of Wall Street experience that focuses on the underserved and widely unknown gems of the small cap and start-up sectors. Many companies like Dataram will be presenting at the Source Capital Conference and looking to deliver their messages in hopes of attracting new money and opportunities.

Twitter (NYSE: TWTR) and Facebook (NASDAQ: FB) were both in this stage of capital raise and business development just a few short years ago. Great ideas are a dime a dozen, but what separates the winners from the losers in the small cap sector is a steadfast commitment to delivering their products and services to the most customers using whatever means necessary.

Hitting the conference circuit to let the money people put a face with a product is essential for developing trust and interest. Any smart investor scours the endless presentations for the few companies that are worth a closer look and, possibly, a capital investment that opens the door for maximized return on investment.

For more information about Source Capital Group, please visit the company’s website at www.sourcegrp.com.

For more information about Dataram Corp., please visit the company’s website at www.dataram.com.

Pets are part of the family these days. We register them in the American Kennel Club or the American Kennel Association; buy them insurance and health plans; make monthly appointments at the groomer and veterinarian; and are projected to spend $61 billion in 2015 on our pets in the U.S. alone, according to the American Pet Products Association. OurPet’s Company (OTC: OPCO) is capitalizing on this already prodigious and constantly growing market with its innovative, high quality product line designed to improve the health, comfort, safety, and enjoyment of pets.

The company markets its products through two brands: the OurPets brand caters to pet specialty customers and consumers and the Pet Zone brand focuses on the needs of the food/drug/mass-market channel and shoppers.

In the third quarter, OurPet’s reported record revenue of $6 million, which was a 7 percent increase from the comparable 2014-quarter. The company also reported a massive 428 percent increase in net income to $410,450, or $0.02 diluted earnings per share, compared to $77,751, or $0.00, for the third quarter of 2014.

Growth is key to determining whether a small company is on the right track. In the third quarter press release, Dr. Steven Tsengas, president and CEO, commented, “We have expanded and strengthened our relationship with several domestic and international independent sales representative organizations, and have added another experienced salesperson to our staff.”

Nearly 100 million households own either a dog or cat, according to the American Pet Products Association, and with the health conscience consumer segment experiencing rapid growth, it is logical to predict that this type of shopper will want to buy the same type of safe, healthy and innovative products for their pets. OurPet’s is poised for a breakout year in 2016 after expanding its product line, distribution cycle and adding more talent to its sales team.

For more information, visit the company’s website at www.ourpets.com

Let us hear your thoughts: OurPet’s Co. Message Board

Legacy Ventures International, Inc. (OTC: LGYV), through wholly-owned subsidiary RM Fresh Brands, recently entered into a distribution agreement with Sysco (NYSE: SYY), a leading marketer and distributor of food products to restaurants, healthcare and educational facilities, hotels and inns and other foodservice and hospitality businesses. Through this partnership, Legacy will look to expand the distribution of Boxed Water, as well as its portfolio of other products, by leveraging Sysco’s network of nearly 200 distribution facilities serving roughly 425,000 customers.

In recent weeks, Legacy has made tremendous progress toward capitalizing on its Canadian distribution rights for Boxed Water, which it secured through the October acquisition of RM Fresh Brands. Just last week, the company announced a distribution deal with Rabba Fine Foods, an influential grocery chain with more than 30 locations across Canada. Legacy has also ramped up efforts to increase awareness of the Boxed Water brand as of late. Last month, the company teamed up with Holt Renfrew, Canada’s premier destination for luxury retail, for its Holiday Kick Off and Charity Shopping Event in order to get the environmentally-friendly bottled water alternative into the hands of prospective customers.

For Legacy, ‘Boxed Water is Better’ isn’t just a slogan, it’s a sustainable message to Canada’s expansive network of retailers. While traditional water bottles take over 1,000 years to biodegrade, Boxed Water is packaged in a deceptively simple, 100 percent recyclable carton that could significantly reduce the environmental impact of the bottled water market in the years to come. According to studies by Cradle to Gate, Boxed Water cartons have less than half of the carbon footprint of PET bottles. This environmental benefit also extends to shipping. According to Legacy, one truckload of modular Boxed Water cartons is the equivalent of 26 truckloads of plastic bottles.

With its newly-announced agreement with Sysco, Legacy continues to make progress toward expanding upon the Canadian retail presence of Boxed Water. Look for the company to capitalize on the marketability of RM Fresh Brands’ portfolio of trend-setting products while continuing to search for additional opportunities to promote sustainable market growth.

For more information, visit www.legacyventuresinc.com

Let us hear your thoughts: Legacy Ventures International, Inc. Message Board

Currently available Parkinson’s disease treatments, while capable of improving the early symptoms of the disease, lose their effect as the disease progresses and produce involuntary writing movements in the patients. As of yet there is no cure for the disease, which is the second most common neurodegenerative disease and affects over 7 million people worldwide. International Stem Cell Corp. (OTC: ISCO), a leader in using pluripotent stem cells in regenerative medicine, this morning issued news regarding its stem cell technology – signaling a potential blockbuster shift it the treatment of Parkinson’s disease.

ISCO today announces that its wholly owned subsidiary, Cyto Therapeutics, has received regulatory approval by the Therapeutics Goods Administration (TGA) of Australia to initiate a phase I/IIa clinical trial, dose escalation trial of human parthenogenetic stem cells-derived neural stem cells (ISC-hpNSC) in patients with moderate to severe Parkinson’s disease.

“We are very pleased to start the first human study of ISC-hpNSC’s for the treatment of this debilitating disease. There is a large unmet medical need for new treatments that may halt or reverse the progression of Parkinson’s disease and we believe our human neural stem cells may fill this need for the millions of people with this disease” stated Andrey Semechkin, PhD, ISCO’s chief executive officer. “We look forward to reporting on the progress of the clinical trial over the coming months.”

ISCO last year announced positive results from its preclinical studies for its ISC-hpNSC therapeutic candidate. In those preclinical studies, the cells demonstrated an improvement in Parkinson’s disease symptoms and increase in brain dopamine levels following the intracranial administration of ISC-hpNSC. The studies further noted that the ISC-hpNSCs provided neurotrophic support and cell replacement to dying dopaminergic neurons.

About the clinical study

The upcoming phase I/IIa clinical study – which will be performed at Royal Melbourne Hospital in Melbourne, Australia – is a dose escalation safety and preliminary efficacy study of human parthenogenetic stem cells-derived neural stem cells (ISC-hpNSC) intracranially transplanted into patients with moderate to severe Parkinson’s disease. The open-label, single center, uncontrolled clinical trial will evaluate three different dose regimens of 30 million-70 million neural cells. A total of 12 participants with moderate to severe Parkinson’s disease will be treated. Following transplantation, the patients will be monitored for 12 months at specified intervals, to evaluate the safety and biologic activity of ISC-hpNSC.

“We are the first company in the world to conduct clinical trials of human pluripotent stem cells based product for the treatment of Parkinson’s disease. We believe the outcome of the study will produce findings in-line with our preclinical studies, where we demonstrated not only safety of our proprietary neural stem cells, but also their functional efficacy. The cells were able to successfully integrate into the brain and provide a significant increase of dopamine levels in the nigrostriatal system” commented Russell Kern, PhD, ISCO’s executive vice president and chief scientific officer.

For more information, visit www.internationalstemcell.com

Let us hear your thoughts: International Stem Cell Corp. Message Board

Nutra Pharma Corp., a biopharmaceutical company engaged in the acquisition, licensing and marketing of homeopathic treatments and ethical drugs for the management of pain, neurological disorders, cancer, auto-immune and infectious diseases, today announces that it has engaged the Corporate Communications Services of QualityStocks. Based in Scottsdale, Arizona, QualityStocks has assisted more than 300 public companies with their efforts to broaden influence, attract growth capital and improve shareholder value over the past 9 years and 11 months.

“We are pleased to have engaged the services of QualityStocks and look forward to a long and fruitful relationship with them as we work to better communicate our progress with shareholders and the general public,” said Nutra Pharma’s chairman and CEO Rik Deitsch. “We believe that Nutra Pharma has an important role to play not only in the traditional ethical arena, but in the less-well-known homeopathic domain as well. We are committed to increasing corporate value through the continued discovery of revolutionary pharmaceutical treatments, expanded distribution reach, and general brand awareness.”

Under the agreement, QualityStocks will strategically use its network of partners, daily and weekly newsletters, social media channels, blog and other outreach tools to relay Nutra Pharma’s corporate message and progress to the investment community.

“QualityStocks enthusiastically welcomes Nutra Pharma,” said Managing Director Michael McCarthy. “Nutra Pharma is one of those progressive pioneering companies that do more than sell products; their work makes our lives better. It is an honor to have the Nutra Pharma team on board and we look forward to helping the company reach its corporate communication goals.”

For more information on the company, visit www.NutraPharma.com

Let us hear your thoughts: Nutra Pharma Corp. Message Board

It’s the most wonderful time of the year and what better way to celebrate the holidays than with a Christmas party at Giggles N’ Hugs (OTC: GIGL) for a little healthy holiday cheer. Santa also recently stopped by in his sleigh to meet with the excited little youngsters, answer wish lists and find out who’s been naughty or nice.

Giggles N’ Hugs adds a much needed healthy, organic and local twist to all its menu items, so, while your kids are enjoying a little playtime, you can munch on some edamame and mahi mahi with a glass of Pinot Grigio to settle your nerves. The Christmas season is meant to be a joyous and happy time spent with family and friends, but everyone likes a deal. That’s why every Tuesday, Giggles N’ Hugs offers its ‘Two for Tuesdays’ promotion – you buy one adult meal and admission for one child, a second child gets in free.

George Bernard Shaw said it best when he stated, “We don’t stop playing because we grow old. We grow old because we stop playing.” Letting go and not taking yourself so seriously all the time is a healthy habit everyone should incorporate into their lives, but doing so in a home or office setting isn’t realistic. Playing with your kids at one of the Giggles N’ Hugs locations could be just what the doctor ordered.

Membership has its privileges, and the company offers several options to save you time and money. Choose from a one, three or six month unlimited play pass for one to three children for a big discount. Also, you can conveniently make these purchases online through the company’s website.

Giggles N’ Hugs has been voted Los Angeles’s #1 Kids Party Place, #1 Family Restaurant, and #1 Indoor Playspace. It has three locations serving the greater Los Angeles area and offers magic shows, puppet shows, DJ’s, face painting, scavenger hunts, dance parties, karaoke and so much more. Come join the fun, and enjoy a healthy snack while your kids have the time of their lives.

For more information, please visit www.gigglesnhugs.com

Let us hear your thoughts: Giggles ‘N Hugs, Inc. Message Board

In November 2015, Agora Holdings, Inc. (OTC: AGHI), through wholly-owned subsidiary Geegle, completed development of TECH, a workflow management application for small- to medium-sized companies (SMEs). TECH simplifies task assignment and was developed to solve some of the logistical problems experienced by companies in the cable and telecommunications industry. Agora’s CEO, Danail Terziev, who holds a master’s in telecommunications, acquired direct knowledge of these problems when he worked at Comcast (NASDAQ: CMCSA) and Rogers Communications (NYSE: RCI). With TECH, telecom technicians can receive, accept, assign, and re-assign work orders received from customers.

TECH is a software nerve center. With it, technicians are always in touch with the office and the office knows the exact status of every job, whether it’s a technician visiting a customer or doing paperwork for that customer. Tasks can be assigned and tracked at anytime from anywhere. TECH pulls together scattered team efforts. It increases team visibility, team productivity and worker accountability by showing who’s working on what, what’s being worked on, and how much time it took. Putting work orders through this internal system improves planning, organization and efficiency as it pins down worker availability, strategically re-assigns work load, and tracks task progress.

TECH helps the technician to be more productive, and it’s a boon to his employer as well. TECH generates data that provides valuable insight into employee performance and customer needs. Future versions of TECH will allow for team chat that can be used to gather feedback from supervisors and team members in real time. Client companies are able to use the software by licensing it for $100 per month. They may also open the software in test mode for a smaller monthly fee to begin creating and executing tasks. To date, interest has been garnered from three cable companies to license the application. Contracts have been sent out and Geegle Operations are awaiting their go-ahead.

Agora Holdings, Inc., together with subsidiary Geegle Media and affiliates, is a leading diversified international family entertainment and media enterprise with five business segments: media networks, TV, studio entertainment, consumer products and interactive media. Agora brings together the best in media and technology. The company is driven by the mission to create the world’s best entertainment and online experiences. It’s dedicated to creating bespoke web products that fulfill the public’s insatiable appetite for social media platforms and apps, TV on Demand, and data storage applications. Operating under the domain name, www.geegle.tv, Geegle Media has, so far, developed a Video on Demand platform which services Canada, the United States, Russia and Bulgaria. Agora’s TECH software is a makeover for the cable guy. No need to be worried about him now.

For more information, visit the company’s website at www.geeglemedia.ca.

Email has become an essential factor for nearly every business in existence today, serving a wide variety of roles ranging from internal communications and business intelligence enabling, to end market engagement and the growth of a given brand’s presence. In fact, a recent report published earlier this year by digital technology-focused analysts eMarketer.com indicates that email use in the U.S. has not only increased some 6.3 percent since 2013 to around 233 million users (72.4 percent market penetration), but that by 2019 overall penetration will hit upwards of 90 percent of all internet users. This is a massive target for businesses and is a major reason why email marketing is still king, despite the growth of social media marketing as a component of an overall marketing effort.

Private internet media heavy-hitter BuzzFeed, for instance, relies heavily on driving traffic back to their site via emails containing original content, and email is routinely one of its top five or six traffic drivers each month, ranking right alongside Twitter and Pinterest. Coming from an entity like BuzzFeed that gets 200-plus million unique visitors each month, news that email traffic grew by around 20 percent in 2013 and 2014 month-over-month should serve as an important lesson to investors and businesses alike about the importance of email to the bottom line.

The eMarketer report mentioned earlier also indicated that around 35.6 percent of internet users actively subscribe to emails from brands in order to stay up to date on the latest news and information, as well as gain access to timely offers or discounts on a given product. However, because email isn’t a standalone storage solution, one of the hottest growth areas today is email archiving solutions, the market for which is expected to maintain a CAGR of nearly 14 percent from 2015 to 2019, according to market research publishing giant Technavio.

Archiving emails and other unstructured data for everything from compliance and risk mitigation, to governance and cost optimization, has become a major focus for SME and enterprise companies, as well as educational institutions and government agencies. In fact, a study from renowned market research, analysis and advisory firm IDC (International Data Corporation) out earlier this year in June, which looked at both the top SaaS (software-as-a-service) companies and ISVs (independent software vendors), indicated that the global archiving software market hit $1.5 billion last year. The strongest growth for the industry is coming from cloud archiving, which is set to deliver a 9.3 percent CAGR through 2019.

Little wonder then that iGambit (OTCQB: IGMB), an extremely lithe, diversified holding company and enterprise incubator focused on early-stage tech companies with viral potential, recently acquired Network Products Guide Product Innovation Award recipient, ArcMail Technology. iGambit subsequently announced the selling off of certain assets of its wholly-owned Gotham Innovation Lab subsidiary, in order to plough the proceeds from the sale directly into the accelerated development of ArcMail’s promising email archiving and management solutions. Solutions aimed not only at providing comprehensive and readily accessible storage, but boosting network performance and satisfying increasingly stringent regulatory requirements as well.

This strategic move by iGambit is perfectly aligned with the company’s core values, which emphasize the targeting and development of such companies as ArcMail that have runaway potential, but which require IGMB’s strategic guidance and operational support in order to take things to the next level. Even in an industry dominated by major players like Rackspace (NYSE: RAX) and Amazon (NASDAQ: AMZN), whose Amazon Web Services was once again top-ranked by marketing, research and advisory firm Gartner this year in cloud IaaS (infrastructure as a service), as well as cloud-connected appliance players like Barracuda (NYSE: CUDA), there is ample room for an investor-accessible company like IGMB, whose now wholly-owned ArcMail subsidiary is geared more towards the SME market.

By providing a diverse array of simplified, affordable solutions that are ideal for smaller companies, which still possess the kind of robust security and broad-spectrum archival capabilities on offer from sector majors, ArcMail is able to hit the sweet spot time and again with stunning agility, directly competing with juggernauts like Amazon, which services companies ranging from Nike (NYSE: NKE) to Siemens (OTC: SIEGY). A good example of this is how ArcMail was chosen by wholly-owned Power Solutions International (NASDAQ: PSIX) subsidiary Power Great Lakes to fulfill its email archiving needs with a secure, readily accessible solution that ensures content is neither altered or deleted.

After extensive due diligence by Power Great Lakes’ IT Manager, involving the vetting of numerous software and appliance based solutions, ArcMail’s flagship Defender™ appliance was chosen to avoid clunky alternatives like storing old mail on Exchange, which is a considerable network performance hit, putting a strain on the server(s) and requiring unwieldy backup times. ArcMail’s Defender line of email archiving hardware has been deployed everywhere from K-12 school districts and universities, to government agencies like the Louisiana Governor’s Office of Homeland Security, and finance concerns such as Franklin Financial Network’s (NYSE: FSB) wholly-owned banking subsidiary, Franklin Synergy Bank.

With a slew of offerings on the table ranging from ArcMail’s fully hosted and managed archiving solution, to cloud-driven archiving through ArcMail’s cloud storage gateway, and virtual machine-driven archiving through a VMware environments-based implementation equivalent to the company’s Defender line, ArcMail has a suite of choices able to satisfy any client’s needs. Moreover, the company has a range of market-driven archiving products like ArcMail Guardian™ that can automatically encode, index and archive inbound, outbound and internal mail, and is designed to be the perfect one-stop-shop appliance solution for Google Apps™ and Office 365 Mail. There is also ArcMail’s solutions for SharePoint™ Files, Salesforce Chatter™ conversations, and social media interactions.

This is a shrewd move for a veteran incubator like iGambit, which has a considerable track record of success with hands-on development of startups into multi-million dollar businesses, all accomplished using its own capital. With a deep bench of veteran executives led by IGMB’s President, Chairman and CEO, John Salerno, who has spent over four decades on the frontlines in public and private computer software and service companies, iGambit has the talent and the vision needed to continue executing on its acquisition and development goals.

The focus for IGMB moving forward will continue to be on acquisition targets that have high-margin, predictable earnings potential, where iGambit can step in and assist with crystallizing the licensing and servicing capabilities that form the foundation of a given recurring revenue model. Long-term stockholder value accretion is the overarching objective for IGMB, which facilitates partner company network growth until such time as the matured entity can be profitability spun-off.

To get a closer look at iGambit’s strategy, visit http://www.igambit.com

In 2014, the largest Ebola epidemic in history struck countries in West Africa, catching the attention of media outlets around the world and reaffirming the destructive power that viruses can have on unprepared civilizations. Viruses come in many shapes and sizes. From relatively inert bugs such as the common cold to dangerous, life-threatening infections like human immunodeficiency virus (HIV), influenza and dengue fever, viruses are found in almost every ecosystem on Earth, making them the most abundant type of biological entity on the planet.

Unlike bacteria, which are mostly harmless and often aid in the function of the human body, viruses are almost always bad news. These tiny organisms attach themselves to healthy cells within the body and, in many cases, reprogram those cells to create new viruses until the cells eventually burst and die. In other cases, viruses transform normal, healthy cells into malignant or cancerous cells. Although viruses are small (the largest virus is still smaller than even the smallest of bacteria), they are vicious. Most viruses target specific cells within the body, such as those in the liver, respiratory system or blood, causing serious, long-term health risks for infected individuals.

Because viruses hijack native cells and reprogram them in order to spread, effectively targeting a virus without harming its host organism’s cells is particularly difficult. When combined with viruses’ ability to mutate in order to counter attempts to inhibit their development, creating a universally effective antiviral medication becomes nearly impossible. Instead, pharmaceutical companies dodge mutations by taking preemptive measures. By administering small, relatively safe doses of viruses to patients, patients’ immune systems can be educated regarding particular viral infections, making future infections much less likely. These doses are known as vaccines.

Vaccines, much like viruses, come in a variety of shapes and sizes, and the world’s largest pharmaceutical companies are continuing to develop and innovative this preemptive treatment option in an effort to keep up with major viral threats. Vaccines are often extremely effective. Measles, for example, is one of the leading causes of death among young children, according to the World Health Organization, but a single dose of the MMR (measles, mumps and rubella) vaccine, which was developed in 1971 by Merck (NYSE: MRK), is 93 percent effective at preventing the deadly virus, according to the Centers for Disease Control and Prevention.

Not all vaccines are as consistently effective as the MMR vaccine, however. Influenza vaccines, such as those regularly developed by Sanofi (NYSE: SNY) and GlaxoSmithKline (NYSE: GSK), demonstrate the limitations of preemptive virus treatment. Because the influenza virus mutates very rapidly, flu shots are developed twice each year, but outbreaks of mutated strains still occur from time to time. To illustrate this, consider the 2009 flu pandemic, which involved the deadly H1N1 influenza virus, commonly known as swine flu. After patients are infected with an unforeseen virus mutation, vaccines are rendered totally ineffective, leaving biopharmaceutical companies to turn to alternative approaches to address these dangerous illnesses.

NanoViricides, Inc. (NYSE MKT: NNVC) is a nano-biopharmaceutical company that’s attempting to usher in a whole new era in medicine. The company’s innovative nanoviricide® antiviral therapeutics are nanomachines that are armed to destroy a particular type of virus. By programming information about a specific virus into the nanoviricide – similar to the postal address on an envelope – the company’s treatment fools a virus that’s already in a person into attaching to it. Shortly after attachment, the nanoviricide encapsulates the virus particle and absorbs its coat proteins. Without those proteins, the virus is unable to bind to a cell, rendering it neutralized and effectively destroyed.

Utilizing its versatile platform technology, NanoViricides is currently developing drugs against a number of viral diseases – including H5N1 bird flu, seasonal influenza, HIV, epidemic keratoconjunctivitis (EKC), hepatitis C, rabies, dengue fever and Ebola virus, among others. The company’s broad-spectrum nanoviricides, which it’s developing to combat several neglected tropical diseases, can bind to as many as 95 percent of known viruses, according to company data. NanoViricides’s most advanced product candidate, injectable FluCide™, is currently being studied in IND-enabling trials for the treatment of severe influenza with hospitalization.

In a quarterly report filed earlier this year, NanoViricides outlined its considerable progress in recent months. In particular, the company highlighted the advancement of its HerpeCide™ program, which it expects to contribute to the ongoing development of topical drugs to control herpes virus outbreaks for a number of indications – including oral lesions and shingles. Assuming positive results from its animal studies, NanoViricides expects these programs to result in extremely effective drugs.

According to its latest financial report, NanoViricides estimates that it has enough cash on hand to perform initial human clinical trials on at least one of its promising drug candidates, as well as advancing at least one additional candidate toward initial clinical trials. With HerpeCide and injectable FluCide currently leading the way, the company is in a favorable strategic position to put its promising therapeutic candidates to the test in the coming months, ahead of potential commercialization. For prospective shareholders, NanoViricides, complete with its innovative approach to targeted antiviral therapeutics, represents an extremely intriguing investment opportunity in the rapidly evolving biopharmaceutical industry.

For more information, visit www.nanoviricides.com

Transitioning to a healthy lifestyle is essential for developing a better quality of life and extending your lifespan. With so many cheap, quick and easy, fast food chains on every corner of America, sometimes that seems like a monumental task, but, in today’s world of smartphone technology and ‘app-hungry’ consumers, Content Checked Holdings, Inc. (OTC: CNCK) is aiding the health conscience shopper with its easy-to-use ContentChecked and SugarChecked apps.

The company’s apps were recently featured in the DIY Active article “Healthy Kitchen Tips: 4 Easy Steps” by clinical nutritionist Tara Zamani where she outlines a guide to healthy living using readily available tips, products, and technology. Zamani emphasizes the importance of getting into the habit of cooking and making it a priority in your life. Once you do this for a while, it becomes fun and is unlike any other activity because of the joys associated with feeling healthier from your own making and, of course, helping your family do the same.

Before jumping into the kitchen, you need the proper ingredients for a healthy concoction. Here is where she illustrates the significance of savvy shopping via ContentChecked’s family of innovative mobile apps. With the SugarChecked app, once you scan a food item, an alert is issued based on personal dietary sugar/sweetener preferences, and then the app provides you with a list of satisfactory alternatives. The ContentChecked app works very similarly, except that it alerts the user based on personal allergy settings and then offers a list of acceptable replacements.

The company’s goal is to continue building an environment that will foster healthier and happier lives through personally targeted information. The key to a healthier way of life is in the palm of your hand thanks to Content Checked Holdings. All you need to do is download the apps and start shopping.

For more information, visit the company’s website at www.ContentChecked.com.